Dana-Farber

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana-Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School. Currently, Dana-Farber is ranked the #3 cancer hospital in the world. Two Nobel laureates in Physiology or Medicine are among its past and present faculty. Dana-Farber's research discoveries include the development of the highly successful Gleevec to treat chronic myeloid leukemia.

Read more in the app

Diet influences survival after stage iii colon cancer, Dana-Farber study finds - EurekAlert!

Dana-Farber researchers identify interventions for breast and colorectal cancer that could redefine standard of care - EurekAlert!

Dana-Farber genomic score predicts progression to multiple myeloma - EurekAlert!

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025 - EurekAlert!

Potential targeted therapy for pediatric brain cancer identified by Dana-Farber team - EurekAlert

Dana-Farber and Gustave Roussy announce 2025 - EurekAlert

Dana-Farber researchers uncover disparities in lived experiences for patients and physicians - EurekAlert

Dana-Farber nurses present research and evidence-based studies at 2024 Oncology Nursing Society Congress - EurekAlert

Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the ... - EurekAlert

Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024 - EurekAlert